Re-defining Parkinson's disease

Archives Italiennes de Biologie

Volumn 151, Issue 4, 2013, Pages 137-142

  Fornai, F ^a,b   Ruggieri, S ^b  

^a UNIVERSITY OF PISA   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Alpha synuclein; Monoamine brainstem disorder (MBD); Parkin disease; Prionoids; Re defining PD

Indexed keywords

EID: 84901350725     PISSN: 00039829     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (50)

1. Ahn T.B., Kim S.Y., Kim J.Y., Park S.S., Lee D.S., Min H.J., Kim Y.K., Kim S.E., Kim J.M., Kim H.J., Cho J., Jeon B.S. alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology, 70: 43-49, 2008
2. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging, 24 (2): 197-211, 2003
3. Burré J., Vivona S., Diao J., Sharma M., Brunger A.T., Südhof T.C. Properties of native brain α-synuclein. Nature, 498: E4-6, 2013
4. Castino R., Lazzeri G., Lenzi P., Bellio N., Follo C., Ferrucci M., Fornai F., Isidoro C. Suppression of autophagy precipitates neuronal cell death following low doses of methamphetamine. J. Neurochem., 106: 1426-1439, 2008
5. Chaudhuri K.R., Rizos A., Sethi K.D. Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? J. Neural. Transm., 120: 1305-1320, 2013
6. Chu Y., Dodiya H., Aebischer P., Olanow C.W., Kordower J.H. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol. Dis., 35: 385-398, 2009
7. Del Tredici K. and Braak H. Spinal cord lesions in sporadic Parkinson's disease. Acta Neuropathol., 124: 643-664, 2012
8. Diao J., Burré J., Vivona S., Cipriano D.J., Sharma M., Kyoung M., Südhof T.C., Brunger A.T. Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. Elife, 2: e00592, 2013
9. Doherty K.M. and Hardy J. Parkin disease and the Lewy body conundrum. Mov Disord., 28: 702-704, 2013
10. Doherty K.M., Silveira-Moriyama L., Parkkinen L., Healy D.G., Farrell M., Mencacci N.E., Ahmed Z., Brett F.M., Hardy J., Quinn N., Counihan T.J., Lynch T., Fox Z.V., Revesz T., Lees A.J., Holton J.L. Parkin disease: a clinicopathologic entity? JAMA Neurol., 70: 571-579, 2013
11. Eisbach S.E. and Outeiro T.F. Alpha-synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology. J. Mol. Med. (Berl.), 91: 693-703, 2013
12. Ferrucci M., Biagioni F., Vivacqua G., Busceti C.L., Bartalucci A., Soldani P., D'Este L., Fumagalli L., Fornai F. The neurobiology of the spinal cord in experimental parkinsonism and Parkinson's disease. Arch. Ital. Biol., 151 (4): 219-234, 2013
13. Fornai F., Lenzi P., Gesi M., Ferrucci M., Lazzeri G., Busceti C.L., Ruffoli R., Soldani P., Ruggieri S., Alessandri M.G., Paparelli A. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci., 23: 8955-8966, 2003a
14. Fornai F., Lenzi P., Gesi M., Ferrucci M., Lazzeri G., Natale G., Ruggieri S., Paparelli A. Recent knowledge on molecular components of Lewy bodies discloses future therapeutic strategies in Parkinson's disease. Curr. Drug. Targets. CNS Neurol. Disord., 2: 149-152, 2003b
15. Fornai F., Lenzi P., Ferrucci M., Lazzeri G., di Poggio A.B., Natale G., Busceti C.L., Biagioni F., Giusiani M., Ruggieri S., Paparelli A. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. Brain Res. Bull., 65: 405-413, 2005a
16. Fornai F., Schlüter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti C.L., Pontarelli F., Battaglia G., Pellegrini A., Nicoletti F., Ruggieri S., Paparelli A., Südhof T.C. Parkinsonlike syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. USA, 102: 3413-3418, 2005b
17. Fornai F., Ferrucci M., Gesi M., Bandettini di Poggio A., Giorgi F.S., Biagioni F., Paparelli A. A hypothesis on prion disorders: are infectious, inherited, and sporadic causes so distinct? Brain Res. Bull., 69: 95-100, 2006
18. Fornai F., Frati A., Gesi M., Fulceri F., Paparelli S., Falleni A., Ruggieri S. Neurobiology and Neuroanatomy of Psychiatric Symptoms in Parkinsonism. Arch. Ital. Biol., 151 (4): 179-191, 2013
19. Gesi M., Lazzeri G., Ferrucci M., Pellegrini A., Lenzi P., Ruggieri S., Fornai F., Paparelli A. Inclusion dynamics in PC12 is comparable between amphetamines and MPTP. Ann. N.Y. Acad. Sci., 1074: 315-319, 2006
20. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., Olanow C.W. Lewy body-like pathology in longterm embryonic nigral transplants in Parkinson's disease. Nat. Med., 14: 504-506, 2008a
21. Kordower J.H., Chu Y., Hauser R.A., Olanow C.W., Freeman T.B. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov. Disord., 23: 2303-2306, 2008b
22. Lazzeri G., Lenzi P., Gesi M., Ferrucci M., Fulceri F., Ruggieri S., Bruno V., Fornai F. In PC12 cells neurotoxicity induced by methamphetamine is related to proteasome inhibition. Ann. N.Y. Acad. Sci., 1074: 174-177, 2006
23. Lazzeri G., Lenzi P., Busceti C.L., Ferrucci M., Falleni A., Bruno V., Paparelli A., Fornai F. Mechanisms involved in the formation of dopamine-induced intracellular bodies within striatal neurons. J. Neurochem., 101: 1414-1427, 2007
24. Lee H.J., Cho E.D., Lee K.W., Kim J.H., Cho S.G., Lee S.J. Autophagic failure promotes the exocytosis and intercellular transfer of α-synuclein. Exp. Mol. Med., 45: e22, 2013
25. Lenzi P., Fulceri F., Lazzeri G., Casini A., Ruggieri S., Paparelli A., Fornai F. Analysis of single, purified inclusions as a novel approach to understand methamphetamine neurotoxicity. Ann. N.Y. Acad. Sci., 1139: 186-190, 2008
26. Lesage S., Anheim M., Letournel F., Bousset L., Honoré A., Rozas N., Pieri L., Madiona K., Dürr A., Melki R., Verny C., Brice A. French Parkinson's Disease Genetics Study Group. G51D α-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome. Ann. Neurol., 73: 459-471, 2013
27. Masuda-Suzukake M., Nonaka T., Hosokawa M., Oikawa T., Arai T., Akiyama H., Mann D.M., Hasegawa M. Prion-like spreading of pathological α-synuclein in brain. Brain, 136 (Pt 4): 1128-1138, 2013
28. Modugno N., Lena F., Di Biasio F., Cerrone G., Ruggieri S., Fornai F. A clinical overview of nonmotor symptoms in Parkinson's Disease. Arch. Ital. Biol., 151 (4): 148-168, 2013
29. Natale G., Kastsiushenka O., Fulceri F., Ruggieri S., Paparelli A., Fornai F. MPTP-induced parkinsonism extends to a subclass of TH-positive neurons in the gut. Brain Res., 1355: 195-206, 2010
30. Natale G., Ferrucci M., Lazzeri G., Paparelli A., Fornai F. Transmission of prions within the gut and towards the central nervous system. Prion, 5: 142-149, 2011a
31. Natale G., Pasquali L., Paparelli A., Fornai F. Parallel manifestations of neuropathologies in the enteric and central nervous systems. Neurogastroenterol. Motil., 23: 1056-1065, 2011b
32. Natale G., Biagioni F., Vivacqua G., D'Este L., Fumagalli L., Fornai F. The neurobiology of dysautonomia in parkinson's disease. Arch. Ital. Biol., 151 (4): 203-218, 2013a
33. Natale G., Pompili E., Biagioni F., Paparelli S., Lenzi P., Fornai F. Histochemical approaches to assess cell-to-cell transmission of misfolded proteins in neurodegenerative diseases. Eur. J. Histochem., 57: e5, 2013b
34. Nolano M., Provitera V., Estraneo A., Selim M.M., Caporaso G., Stancanelli A., Saltalamacchia A.M., Lanzillo B., Santoro L. Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. Brain, 131 (Pt 7): 1903-1911, 2008
35. Olanow C.W. and Prusiner S.B. Is Parkinson's disease a prion disorder? Proc. Natl. Acad. Sci. USA, 106: 12571-12572, 2009
36. Pasanen P., Myllykangas L., Siitonen M., Raunio A., Kaakkola S., Lyytinen J., Tienari P.J., Pöyhönen M, Paetau A. A novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol. Aging., pii: S0197-4580(14)00281-4, 2014. doi:10.1016/j.neurobiolaging.2014.03.024
37. Pifl C., Kish S.J., Hornykiewicz O. Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms. Mov. Disord., 27: 1618-1624, 2012
38. Pifl C., Hornykiewicz O., Blesa J., Adánez R., Cavada C., Obeso J.A. Reduced noradrenaline, but not dopamine and serotonin in motor thalamus of the MPTP primate: relation to severity of parkinsonism. J. Neurochem., 125: 657-662, 2013
39. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276: 2045-2047, 1997
40. Recasens A., Dehay B., Bové J., Carballo-Carbajal I., Dovero S., Pérez-Villalba A., Fernagut P.O., Blesa J., Parent A., Perier C., Fariñas I., Obeso J.A., Bezard E., Vila M. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol., 75: 351-362, 2014
41. Sahay S., Anoop A., Krishnamoorthy G., Maji S.K. Site-specific fluorescence dynamics of α-synuclein fibrils using time-resolved fluorescence studies: effect of familial Parkinson's disease-associated mutations. Biochemistry, 53: 807-809, 2014
42. Samantaray S., Knaryan V.H., Butler J.T., Ray S.K., Banik N.L. Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP. J. Neurochem., 104: 1309-1320, 2008
43. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302: 841, 2003
44. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature, 388: 839-840, 1997
45. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA, 95: 6469-6473, 1998
46. Ubeda-Bañon I., Saiz-Sanchez D., de la Rosa-Prieto C., Martinez-Marcos A. α-Synuclein in the olfactory system in Parkinson's disease: role of neural connections on spreading pathology. Brain Struct. Funct., 2013
47. Usenovic M. and Krainc D. Lysosomal dysfunction in neurodegeneration: the role of ATP13A2/ PARK9. Autophagy, 8: 987-988, 2012
48. Vanacore N. and Lacorte E. Methodological issues on the epidemiology of non motor symptoms in parkinson's disease. Arch. It. Biol., 151 (4): 143-147, 2013
49. Vivacqua G., Casini A., Vaccaro R., Salvi E.P., Pasquali L., Fornai F., Yu S., D'Este L. Spinal cord and parkinsonism: neuromorphological evidences in humans and experimental studies. J. Chem. Neuroanat., 42: 327-340, 2011
50. Vivacqua G., Biagioni F., Yu S., Casini A., Bucci D., D'Este L., Fornai F. Loss of spinal motor neurons and alteration of alpha-synuclein immunostaining in MPTP induced Parkinsonism in mice. J. Chem. Neuroanat., 44: 76-85, 2012